1659P The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials.

MLA

Letissier, O., et al. “1659P The Use of Liquid Biopsy in Patients with Advanced Pancreatic Cancer (PDAC) to Guide Enrollment in Phase I Clinical Trials.” Annals of Oncology, vol. 34, Oct. 2023, pp. S913–14. EBSCOhost, https://doi.org/10.1016/j.annonc.2023.09.2608.

APA

Letissier, O., Smolenschi, C., Hollebecque, A., Vasseur, D., Champiat, S., Bahleda, R., Gazzah, A., Michot, J.-M., Danlos, F.-X., Ouali, K., Henon, C., Mahjoubi, L., Goldschmidt, V., Loriot, Y., Massard, C., Bayle, A., Italiano, A., Baldini, C., & Ponce Aix, S. (2023). 1659P The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials. Annals of Oncology, 34, S913–S914. https://doi.org/10.1016/j.annonc.2023.09.2608

Chicago

Letissier, O., C. Smolenschi, A. Hollebecque, D. Vasseur, S. Champiat, R. Bahleda, A. Gazzah, et al. 2023. “1659P The Use of Liquid Biopsy in Patients with Advanced Pancreatic Cancer (PDAC) to Guide Enrollment in Phase I Clinical Trials.” Annals of Oncology 34 (October): S913–14. doi:10.1016/j.annonc.2023.09.2608.